Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease

Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease

We report a 64-year-old female case of intractable adult-onset Still's disease (AOSD). Initial high-dose steroid therapy combined with cyclosporin A was ineffective against macrophage-activation syndrome (MAS), which was accompanied by the systemic type of AOSD. Treatment for MAS with intraveno...

Full description

Bibliographic Details
Main Authors: Tsuji, Yoshika, Iwanaga, Nozomi, Adachi, Anna, Tsunozaki, Kinuyo, Izumi, Yasumori, Moriwaki, Yuji, Kurohama, Kazuhiro, Ito, Masahiro, Kawakami, Atsushi, Migita, Kiyoshi
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700153/
id pubmed-4700153
recordtype oai_dc
spelling pubmed-47001532016-01-21 Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease Tsuji, Yoshika Iwanaga, Nozomi Adachi, Anna Tsunozaki, Kinuyo Izumi, Yasumori Moriwaki, Yuji Kurohama, Kazuhiro Ito, Masahiro Kawakami, Atsushi Migita, Kiyoshi Case Report We report a 64-year-old female case of intractable adult-onset Still's disease (AOSD). Initial high-dose steroid therapy combined with cyclosporin A was ineffective against macrophage-activation syndrome (MAS), which was accompanied by the systemic type of AOSD. Treatment for MAS with intravenous cyclophosphamide resulted in remission of AOSD and a reduction in the high doses of steroids. Efficacy of biologics against MAS in AOSD is unclear. Cyclophosphamide, a conventional cytotoxic agent, should be considered as one of the therapeutic options for refractory types of AOSD with MAS. Hindawi Publishing Corporation 2015 2015-12-22 /pmc/articles/PMC4700153/ /pubmed/26798538 http://dx.doi.org/10.1155/2015/163952 Text en Copyright © 2015 Yoshika Tsuji et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Tsuji, Yoshika
Iwanaga, Nozomi
Adachi, Anna
Tsunozaki, Kinuyo
Izumi, Yasumori
Moriwaki, Yuji
Kurohama, Kazuhiro
Ito, Masahiro
Kawakami, Atsushi
Migita, Kiyoshi
spellingShingle Tsuji, Yoshika
Iwanaga, Nozomi
Adachi, Anna
Tsunozaki, Kinuyo
Izumi, Yasumori
Moriwaki, Yuji
Kurohama, Kazuhiro
Ito, Masahiro
Kawakami, Atsushi
Migita, Kiyoshi
Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease
author_facet Tsuji, Yoshika
Iwanaga, Nozomi
Adachi, Anna
Tsunozaki, Kinuyo
Izumi, Yasumori
Moriwaki, Yuji
Kurohama, Kazuhiro
Ito, Masahiro
Kawakami, Atsushi
Migita, Kiyoshi
author_sort Tsuji, Yoshika
title Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease
title_short Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease
title_full Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease
title_fullStr Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease
title_full_unstemmed Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease
title_sort successful treatment with intravenous cyclophosphamide for refractory adult-onset still's disease
description We report a 64-year-old female case of intractable adult-onset Still's disease (AOSD). Initial high-dose steroid therapy combined with cyclosporin A was ineffective against macrophage-activation syndrome (MAS), which was accompanied by the systemic type of AOSD. Treatment for MAS with intravenous cyclophosphamide resulted in remission of AOSD and a reduction in the high doses of steroids. Efficacy of biologics against MAS in AOSD is unclear. Cyclophosphamide, a conventional cytotoxic agent, should be considered as one of the therapeutic options for refractory types of AOSD with MAS.
publisher Hindawi Publishing Corporation
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700153/
_version_ 1613519584090914816

Similar Items